Skip to main content

Table 1 FSGS Patient demographic and clinical characteristics

From: Treatment of post-transplant recurrent FSGS in children using plasmapheresis and augmentation of immunosuppression

Characteristics

N = 17

Male,n(%)

11 (64.7)

Age at trasplant, years. Median (IQR)

14.3 (10.8–17.2)

Time between diagnosis and transplant, years. Median (IQR)

5.8 (3.9–7.4)

Donant type, n(%)

 Live donor

10 (58.8)

 Deceased donor

7 (41.2)

Antropometrical measurements,

 Weight [Kg], median (IQR)

34 (26–48)

 Weight z-score, mean (±SD)

−1.1 (1.2)

 Height [cm], median (IQR)

150 (124–155)

 Height z-score, mean (±SD)

−1.8 (0.9)

 BMI [Kg/m2], median (IQR)

18.3 (15.2–19.3)

 BMI z-score, mean (±SD)

−0.7 (1.1)

Previous nephrectomy,n(%)

10 (58.8)

Pre-transplant Plasmapheresis,n(%)

8 (47.1)

Pre-transplant dialysis modality,n(%)

 Hemodialysis

10 (58.8)

 Peritoneal dialysis,

8 (47.1)

Induction therapy,n(%)

 Thymoglobulin

5 (29.4)

 Basiliximab

5 (29.4)

 Daclizumab

7 (41.2)

Patients Undergoing Plasmapheresis,n(%)

 Plasmapheresis procedures, median (IQR)

9 (6–11)

Remission with therapy,n(%)

 Live donor

5/7

 Deceased donor

7/10

Acute Rejection,n(%)

3 (17.7)

Injert Lost,n(%)

8 (35.3)

Length of hospital stay (days), median (IQR)

28 (19–46)

Death,n(%)

5 (29.4)